Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium

doi:10.1093/schbul/sbad112

. 2024 Jan 1;50(1):5-8.

doi: 10.1093/schbul/sbad112.

Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium

Sanne Koops¹, Kelly Allott^{2

3}, Lieuwe de Haan^{4

5}, Eric Chen⁶, Christy Hui⁶, Eoin Killackey^{2

3}, Maria Long^{7

8}, Joanna Moncrieff⁷, Iris Sommer¹, Anne Emilie Stürup⁹, Lex Wunderink¹, Marieke Begemann¹; TAPER international research consortium

Collaborators, Affiliations

Collaborators

TAPER international research consortium:
J (Julia) van der A¹⁰

Affiliations

¹ Department of Psychiatry, University Medical Center Groningen, Rijksuniversiteit Groningen, Groningen, The Netherlands.
² Orygen, Melbourne, VIC, Australia.
³ Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.
⁴ Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands.
⁵ Arkin, Institute for Mental Health, Amsterdam, The Netherlands.
⁶ Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.
⁷ Division of Psychiatry, University College London, London, United Kingdom.
⁸ Department of Health Services Research and Management, City University, London, United Kingdom.
⁹ Copenhagen Research Center for Mental Health (CORE), Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
¹⁰ Department of Psychiatry, University Medical Center Groningen (UMCG), Rijksuniversiteit Groningen (RUG), Groningen, Netherlands

PMID: 37625022
PMCID: PMC10754158
DOI: 10.1093/schbul/sbad112

Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium

Sanne Koops et al. Schizophr Bull. 2024.

. 2024 Jan 1;50(1):5-8.

doi: 10.1093/schbul/sbad112.

Authors

Collaborators

TAPER international research consortium:
J (Julia) van der A¹⁰

Affiliations

¹ Department of Psychiatry, University Medical Center Groningen, Rijksuniversiteit Groningen, Groningen, The Netherlands.
² Orygen, Melbourne, VIC, Australia.
³ Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.
⁴ Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands.
⁵ Arkin, Institute for Mental Health, Amsterdam, The Netherlands.
⁶ Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.
⁷ Division of Psychiatry, University College London, London, United Kingdom.
⁸ Department of Health Services Research and Management, City University, London, United Kingdom.
⁹ Copenhagen Research Center for Mental Health (CORE), Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
¹⁰ Department of Psychiatry, University Medical Center Groningen (UMCG), Rijksuniversiteit Groningen (RUG), Groningen, Netherlands

PMID: 37625022
PMCID: PMC10754158
DOI: 10.1093/schbul/sbad112

Erratum in

Correction to: Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.
[No authors listed] [No authors listed] Schizophr Bull. 2024 Jan 1;50(1):228-229. doi: 10.1093/schbul/sbad135. Schizophr Bull. 2024. PMID: 37713624 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Cited by

Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed.
Gangadin SS, de Beer F, Wijnen B, Begemann M, van Beveren N, Boonstra N, de Haan L, Kikkert M, Koops S, van Os J, Veling W, Wiersma S; HAMLETT‐OPHELIA Consortium; Sommer IEC. Gangadin SS, et al. World Psychiatry. 2025 Jun;24(2):240-249. doi: 10.1002/wps.21315. World Psychiatry. 2025. PMID: 40371797 Free PMC article.
Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles.
Horowitz MA, Moncrieff J. Horowitz MA, et al. Curr Opin Psychiatry. 2024 Jul 1;37(4):320-330. doi: 10.1097/YCO.0000000000000940. Epub 2024 May 9. Curr Opin Psychiatry. 2024. PMID: 38726815 Free PMC article. Review.
Verification of successful maintenance by serum drug level during a guided antipsychotic reduction to reach minimum effective dose (GARMED) trial.
Liu CI, Liu CM, Chiu HH, Chuang CC, Hwang TJ, Hsieh MH, Chien YL, Lin YT, Yen K, Liu CC. Liu CI, et al. Psychol Med. 2024 Sep 26;54(14):1-11. doi: 10.1017/S0033291724002356. Online ahead of print. Psychol Med. 2024. PMID: 39324399 Free PMC article.
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs.
O'Neill JR, Taylor DM, Horowitz MA. O'Neill JR, et al. Ther Adv Psychopharmacol. 2024 Sep 12;14:20451253241272790. doi: 10.1177/20451253241272790. eCollection 2024. Ther Adv Psychopharmacol. 2024. PMID: 39282238 Free PMC article.

References

1. Cunningham Owens D, Johnstone EC.. The development of antipsychotic drugs. Brain Neurosci Adv. 2018;2:2398212818817498. doi: 10.1177/2398212818817498 - DOI - PMC - PubMed
1. National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management. London; 2014. - PubMed
1. Fitton R, Sweetman J, Heseltine-Carp W, van der Feltz-Cornelis C.. Anti-inflammatory medications for the treatment of mental disorders: a scoping review. Brain, Behav Immun Health. 2022;26:100518. - PMC - PubMed
1. Sommer IE, Gangadin SS, de Witte LD, et al. . Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial. Schizophr Bull. 2021;47(4):1108–1115. doi: 10.1093/schbul/sbab010 - DOI - PMC - PubMed
1. Allott K, McGorry PD, Yuen HP, et al. . The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neurocognition in first-episode psychosis. Biol Psychiatry. 2019;86(1):35–44. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Cunningham Owens D, Johnstone EC.. The development of antipsychotic drugs. Brain Neurosci Adv. 2018;2:2398212818817498. doi: 10.1177/2398212818817498 - DOI - PMC - PubMed

[2] Cunningham Owens D, Johnstone EC.. The development of antipsychotic drugs. Brain Neurosci Adv. 2018;2:2398212818817498. doi: 10.1177/2398212818817498 - DOI - PMC - PubMed

[3] National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management. London; 2014. - PubMed

[4] National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management. London; 2014. - PubMed

[5] Fitton R, Sweetman J, Heseltine-Carp W, van der Feltz-Cornelis C.. Anti-inflammatory medications for the treatment of mental disorders: a scoping review. Brain, Behav Immun Health. 2022;26:100518. - PMC - PubMed

[6] Fitton R, Sweetman J, Heseltine-Carp W, van der Feltz-Cornelis C.. Anti-inflammatory medications for the treatment of mental disorders: a scoping review. Brain, Behav Immun Health. 2022;26:100518. - PMC - PubMed

[7] Sommer IE, Gangadin SS, de Witte LD, et al. . Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial. Schizophr Bull. 2021;47(4):1108–1115. doi: 10.1093/schbul/sbab010 - DOI - PMC - PubMed

[8] Sommer IE, Gangadin SS, de Witte LD, et al. . Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial. Schizophr Bull. 2021;47(4):1108–1115. doi: 10.1093/schbul/sbab010 - DOI - PMC - PubMed

[9] Allott K, McGorry PD, Yuen HP, et al. . The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neurocognition in first-episode psychosis. Biol Psychiatry. 2019;86(1):35–44. - PubMed

[10] Allott K, McGorry PD, Yuen HP, et al. . The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neurocognition in first-episode psychosis. Biol Psychiatry. 2019;86(1):35–44. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium

Collaborators

Affiliations

Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium

Authors

Collaborators

Affiliations

Erratum in

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous